Pivlatz IV infusion 150mg, manufactured by Nexella Pharma Japan, contains Clazosentan sodium, a selective endothelin receptor antagonist. It is approved in Japan for the prevention of cerebral vasospasm and related cerebral ischemic symptoms following aneurysmal subarachnoid hemorrhage. YJ code: 2190418A1023, standard: 150mg 6mL 1 bottle.
Pivlatz IV infusion 150mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →
